FOP News

University of Michigan Publishes Article Identifying Different Immune Cell Types Post Injury

Read more Share

Important Announcement and Letter from Ipsen Regarding the MOVE Trial and a Pause in Dosing

Read more Share

Regeneron Releases Phase 2 Trial Results and Shares Next Steps

Read more Share

Regeneron Pharmaceutical Releases Results of Phase 2 of the LUMINA-1 Trial

Read more Share

An Important Update from Ipsen Regarding the Palovarotene Trial for Children Under 14

Read more Share

Important Announcement about the MOVE Trial for Children Under 14

Read more Share

Exciting News from BioCryst Pharmaceuticals

BioCryst launches Phase 1 trial for FOP

Read more Share

An Important Announcement from Blueprint Medicines & Ipsen

Ipsen and Blueprint enter exclusive agreement in FOP

Read more Share

ASBMR 2019 Presentations

11 FOP Presentations Will Be Made At The Annual Meeting

Read more Share

Dr. Maurizio Pacifici’s Research Inspired Two Clinical Trials

Learn how research on RAR gamma agonists motivated the Palovarotene clinical trials  

Read more Share

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter